Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

25.0%

2 terminated/withdrawn out of 8 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

67%

4 of 6 completed trials have results

Key Signals

4 with results

Enrollment Performance

Analytics

Phase 1
4(50.0%)
Phase 2
4(50.0%)
8Total
Phase 1(4)
Phase 2(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials
NCT04488419Phase 2Completed

ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease

Role: lead

NCT04886063Phase 2Terminated

Open Label Study of ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease

Role: lead

NCT04831281Phase 2Terminated

ATH-1017 Treatment in Subjects With Parkinson's Disease Dementia or Dementia With Lewy Bodies (SHAPE Trial)

Role: lead

NCT06432647Phase 1Completed

A SAD and MAD Study of the Safety, Tolerability, and Pharmacokinetics of ATH-1105

Role: lead

NCT05169671Phase 1Completed

Safety, Tolerability, and Pharmacokinetics Study of ATH-1020

Role: lead

NCT04491006Phase 2Completed

A Study of ATH-1017 in Mild to Moderate Alzheimer's Disease

Role: lead

NCT05511558Phase 1Completed

A Study of the Absorption, Metabolism, and Excretion of [14C]-Fosgonimeton (ATH-1017)

Role: lead

NCT03298672Phase 1Completed

Safety, Tolerability, and Pharmacokinetics Study of NDX-1017

Role: lead

All 8 trials loaded